CEBPA (CCAAT enhancer binding protein alpha) is a key transcription factor that regulates myeloid differentiation and serves as a critical prognostic marker in acute myeloid leukemia (AML). The protein functions as a DNA-binding transcription factor that enhances gene expression, particularly of differentiation-promoting genes like claudin-5 in endothelial cells 1. In AML, CEBPA mutations occur in 5-15% of cases and are classified into single (CEBPAsm) or double (CEBPAdm) mutations affecting different protein domains 23. Mechanistically, mutations in the basic leucine zipper (bZIP) domain, particularly in-frame insertions/deletions (bZIPInDel), are the primary determinants of favorable prognosis in CEBPA-mutant AML 45. These bZIP mutations confer superior complete remission rates and overall survival compared to other CEBPA mutation types. The protein's function is regulated through complex interactions with other transcription factors including GATA2, with TET2 co-mutations affecting GATA2 expression levels and disease aggressiveness 6. Additionally, CEBPA can be repressed by oncogenic factors like MECOM, which blocks differentiation programs and drives aggressive leukemia phenotypes 7. Clinically, CEBPA bZIP mutations serve as powerful independent prognostic indicators, with potential implications for treatment stratification and targeted therapeutic approaches in AML patients.